Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fosphenytoin Sodium,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NPC-06 to Pain Associated With Acute Herpes Zoster
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 29, 2022
Lead Product(s) : Fosphenytoin Sodium,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fosphenytoin Sodium,Inapplicable
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ready-to-dilute and room temperature stable, SESQUIENT is the only FDA-approved fosphenytoin that allows point-of-care storage, as well as fast and efficient administration in emergency rooms and intensive care units.
Product Name : Sesquient
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 11, 2020
Lead Product(s) : Fosphenytoin Sodium,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fosphenytoin Sodium,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NPC-06 to Acute Pain in Herpes Zoster
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 25, 2019
Lead Product(s) : Fosphenytoin Sodium,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fosphenytoin Sodium,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase II Clinical Trial of NPC-06 in Patients With Neuropathic Pain in Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 12, 2018
Lead Product(s) : Fosphenytoin Sodium,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fosphenytoin Sodium,Lacosamide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : UCB Pharma S.A
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 25, 2011
Lead Product(s) : Fosphenytoin Sodium,Lacosamide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : UCB Pharma S.A
Deal Size : Inapplicable
Deal Type : Inapplicable